Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Inclusion Criteria: * Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information \[PHI\]) * Aged 18-70 at the time of informed consent * Must have a relapsing or progressive form of MS * Plan to begin Ocrevus™ treatment but have not actually had first treatment yet * Male subjects and female subjects of child-bearing potential (including female subjects who are not post-menopausal for at least 1 year) must be willing to practice effective contraception (as defined by the investigator) during the study and be willing and able to continue contraception for 6 months after their last dose of study treatment * EDSS 4.0-8.0 * UE weakness in at least one limb, defined as grade 4/5 in ≥ 2 muscles per limb * Muscle weakness must be primarily related to MS * Joint range of motion must be within functional limits * Patient must be able to perform 9HPT and TEMPA tests with at least one limb Exclusion Criteria: * Prior treatment with Ocrevus™ (Cannot already be on Ocrevus prior to joining the study) * Severe weakness in bilateral upper limbs causing complete loss of function * History of severe allergic or anaphylactic reactions or known drug hypersensitivity * Female subjects considering becoming pregnant while in the study * Female subjects who are currently pregnant or breast-feeding * Unwillingness or inability to comply with the requirements of the protocol including the presence of any conditional (physical, mental or socia…